[x]
Create

Here is what users have to say about Genentech

useravatar
Entry added by CWAnswers Join us and contribute your knowledge as well.
Comment
Share this
Share with a friend: genentech
Your name
Your email
Recipient Email

Genentech Inc. (NYSE: DNA), a composite of Genetic Engineering Technology, Inc., is a leading biotechnology corporation, which was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. "Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a fateful meeting in 1976, the two decided to start the first biotechnology company, Genentech." It is considered to have founded the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology (the company's ticker symbol reflects Boyer's contribution to the field). Boyer with a fellow researcher, Stanley Norman Cohen, in 1973, invented recombinant genetic engineering, by realizing that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Robert Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with insulin in 1978.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply sign up and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks for Genentech

Top 10 for Genentech

Things about Genentech you find nowhere else.

Select content modules

Comments about Genentech

Please leave your comment using the comment button above the article
Share with a friend: genentech
Your name
Your email
Recipient Email

Images found for Genentech

Genentech 1Genentech 2Genentech 3
Genentech 4Genentech 5Genentech 6
Genentech 7Genentech 8Genentech 9

Wikipedia About Genentech

Genentech Inc. (NYSE: DNA), a composite of Genetic Engineering Technology, Inc., is a leading biotechnology corporation, which was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. "Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a fateful meeting in 1976, the two decided to start the first biotechnology company, Genentech." It is considered to have founded the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology (the company's ticker symbol reflects Boyer's contribution to the field). Boyer with a fellow researcher, Stanley Norman Cohen, in 1973, invented recombinant genetic engineering, by realizing that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Robert Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with insulin in 1978.

As of March 2008, Genentech employs more than 11,000 people and Arthur D. Levinson is the Chairman and CEO. The Swiss pharmaceutical conglomerate Hoffmann-La Roche owns the majority of Genentech shares and has offered to buy the remaining.

Product Timeline

  • 1982 - Synthetic "human" insulin approved by the U.S. Food and Drug Administration (FDA), thanks largely to its partnership with insulin manufacturer Eli Lilly and Company, who shepherded the product through the FDA approval process. The product (Humulin) was licensed to and manufactured by Lilly, and was the first-ever approved genetically engineered human therapeutic.
  • 1985 - Protropin (somatrem) - Supplementary growth hormone for children with growth hormone deficiency (ceased manufacturing December 2002).
  • 1987 - Activase (recombinant tissue plasminogen activator) - To dissolve blood clots in patients with acute myocardial infarction. Also used to treat non-hemorrhagic stroke.
  • 1990 - Actimmune (interferon gamma 1b) - Treatment of chronic granulomatous disease (licensed to Intermune).
  • 1993 - Nutropin (recombinant somatropin) - Growth hormone for children and adults for treatment before kidney transplant due to chronic renal insufficiency.
  • 1994 - Pulmozyme (dornase alfa) - Inhalation treatment for children and young adults with cystic fibrosis - recombinant DNAse.
  • 1997 - Rituxan (rituximab)- Treatment for specific kinds of non-Hodgkins lymphomas.
  • 1998 - Herceptin (trastuzumab) - Treatment for metastatic breast cancer patients with tumors that overexpress the HER2 gene. Recently approved for adjuvant therapy for breast cancer.
  • 2000 - TNKase (tenecteplase) - "Clot-busting" drug to treat acute myocardial infarction.
  • 2003 - Xolair (omalizumab) - Subcutaneous injection for moderate to severe persistent asthma.
  • 2003 - Raptiva (efalizumab) - Antibody designed to block the activation and reactivation of T cells that lead to the development of psoriasis. Developed in partnership with XOMA
  • 2004 - Avastin (bevacizumab) - Anti-VEGF monoclonal antibody for the treatment of metastatic cancer of the colon or rectum.
  • 2004 - Tarceva (erlotinib) - Treatment for patients with locally advanced or metastatic non-small cell lung cancer, and pancreatic cancer.
  • 2006 - Lucentis (ranibizumab injection) - The U.S. Food and Drug Administration (FDA) has approved LUCENTIS(TM) (ranibizumab injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA approved LUCENTIS after a Priority Review (six-month). Genentech started shipping product on June 30, 2006, the day the product was approved.

Search results for Genentech

DNA: Profile for GENENTECH INC - Yahoo! Finance

See the company profile for GENENTECH INC (DNA) including business summary, industry/sector information, number of employees, business summary, corporate governance, ...finance.yahoo.com/q/pr?s=DNA

DNA: Summary for GENENTECH INC - Yahoo! Finance

Get detailed information on GENENTECH INC (DNA) including quote performance, ... Genentech Deal Spells End for Roche Lab in California at The Wall Street Journal ...finance.yahoo.com/q?s=dna

100 Best Companies to Work For 2007: Genentech snapshot | FORTUNE

Companies Economy International Corrections Pre-market trading ... 2. Genentech (DNA) What makes it so great? Biotech leader has uncommonly loyal staffers. ...money.cnn.com/magazines/fortune/bestcompanies/2007/snapshots...

BioSpace - Genentech, Inc. News, Search Jobs, Events

Genentech, the founder of the biotechnology industry, is a company with a ... Today, Genentech manufactures and commercializes multiple protein-based ...www.biospace.com/company_profile.aspx?CompanyId=1384

Genentech Data Bring Jitters - TheStreet.com

CHICAGO -- The annual meeting of the American Society of Clinical Oncology has traditionally been the forum... Read this article and other financial news at ...www.thestreet.com/newsanalysis/biotech/10360276.html

Images found for Genentech

Genentech 1Genentech 2Genentech 3
Genentech 4Genentech 5Genentech 6
Genentech 7Genentech 8Genentech 9

News about Genentech

Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy

Business Wire via Yahoo! Finance SCHLIEREN/BASEL, Switzerland & SOUTH SAN FRANCISCO, Calif.----Genentech, Inc. , GlycArt, a company wholly-owned by Roche, and Roche have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt's GA101 molecule.http://biz.yahoo.com/bw/081003/20081002006455.html?.v=1

Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient

Finanzen.net Genentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a ...http://www.finanzen.net/nachricht/Genentech_Issues_Dear_Heal...

Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient

Centre Daily TimesGenentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy (PML) in a 70-year old patient who had received Raptiva(R) (efalizumab) for more than four years for treatment of chronic plaque psoriasis. The company will work with the U.S. Food and Drug Administration .....http://www.centredaily.com/business/technology/story/880430....

Will the Tight Credit Market Kill Roche's Bid for Genentech?

Schaeffers ResearchThe shares of Genentech Inc. (DNA: sentiment, chart, options) were raised this morning from "market perform" to "outperform" at William Blair, despite a few nagging concerns about the stock's potential acquisition by Roche...( Read More )http://www.schaeffersresearch.com/commentary/optionbytes.asp...

Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient

Business Wire via Yahoo! Finance SOUTH SAN FRANCISCO, Calif.----Genentech, Inc. announced today that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy in a 70-year old patient who had received Raptiva® for more than four years for treatment of chronic plaque psoriasis.http://biz.yahoo.com/bw/081002/20081002006372.html?.v=1

News about Genentech

Genentech touts test of Rituxan plus chemo vs. leukemia

East Bay Business TimesGenentech touts test of Rituxan plus chemo vs. leukemia Companies heed Bush's call to battle Genentech to work on lung cancer drug test Dow doomsday denied, or delayed? Index drops, then climbs again Dow drops like it's 1999 and closes below 10,000 ... http://eastbay.bizjournals.com/eastbay/stories/2008/10/06/da...

Two drugs don't boost lung cancer survival

San Diego Union-TribuneZURICH/LONDON – Roche Holding AG and Genentech Inc said on Monday a study into the benefits of combining their Tarceva and Avastin drugs for lung cancer patients did not show an increase in overall survival. Both drugs are targeted therapies ... http://www.signonsandiego.com/news/health/20081006-0244-roch...

Genentech Drug Rituxan Slows Progession Of Leukemia

dbtechno.comWashington (dbTechno) - Genentech has come out and stated that their drug Rituxan was successful in slowing the progression of lymphocytic leukemia in a late-stage trial. The late-stage trial treated the patients who all had relapses following ... http://www.dbtechno.com/health/2008/10/08/genentech-drug-rit...

UPDATE 1-Roche says lung cancer study did not boost survival

ReutersZURICH, Oct 6 (Reuters) - Roche Holding AG (ROG.VX: Quote , Profile , Research , Stock Buzz ) and Genentech Inc (DNA.N: Quote , Profile , Research , Stock Buzz ) said on Monday a study into the benefits of combining two of their drugs for patients ... http://www.reuters.com/article/rbssHealthcareNews/idUSL64646...

Genentech Study Failure Highlights Pitfalls of Cancer Drug Combos

Wall Street JournalCombining two targeted lung cancer drugs — Avastin and Tarceva — didn’t extend lives any more than giving patients Tarceva alone, Genentech said . (Genentech sells Avastin in the U.S., and it co-markets Tarceva with OSI Pharmaceuticals ... http://blogs.wsj.com/health/2008/10/07/genentech-study-failu...

Search results for Genentech

DNA: Summary for GENENTECH INC - Yahoo! Finance

Get detailed information on GENENTECH INC (DNA) including quote performance, Real-Time ECN, technical chart analysis, key stats, insider transactions, and the latest company ... http://finance.yahoo.com/q?s=DNA

Genentech Radiation Safety Training : Log On or Register

If you have already received validation from the Genentech radiation safety staff, then log on below as a Registered User.http://genentech.radtrainonline.com/?source=RSA

Genentech - Company Overview - Hoover's

The few, the proud, the profitable" could be Genentech's motto. One of the world's most successful biotechs (in an industry full of... Full Company Description for Genentechhttp://www.hoovers.com/genentech/--ID__10628--/free-co-facts...

100 Best Companies to Work For 2008: Genentech snapshot | FORTUNE

What qualities are you looking for in a great employer? Use our tool to find the companies on our list that suit you best.http://money.cnn.com/magazines/fortune/bestcompanies/2008/sn...

DNA - Genentech, Inc. - Google Finance

Get the latest on Genentech, Inc. (DNA) including stock quotes, interactive charts, up to date news, high quality discussion groups and more on Google Finance.http://finance.google.com/finance?q=NYSE:DNA
  • Recent
  • Mine
  • Watched
  • Commented
You must be logged in to perform this operation
You must be logged in to perform this operation

Search this site

Videos found for Genentech

Genentech - Driven by Science

Genentech - Driven by ScienceInterview with Joseph McCrackenFlash - Video

ISRAEL / LEBANON: Conflict: Day 20:...

ISRAEL / LEBANON: Conflict: Day 20: Blair makes US visit to Genentech laboratory in CaliforniaBritish Prime Minister Tony Blair MP visits the Genentech biotech laboratories in California, while at home senior cabinet ministers are having to rally round him amid growing...MPEG 4 - Video

Broker Action: Genentech

Broker Action: Genentech(90 sec.) Plus, analyst action on Mattel and GM.Flash - Video

Genentech Earnings Reaction

Genentech Earnings ReactionGenentech Earnings ReactionFlash - Video

Roche's Genentech Bid, No Ordinary ...

Roche's Genentech Bid, No Ordinary OfferSwiss pharmaceutical company Roche offers to buy the roughly 44% of U.S. biotech firm Genentech it doesn't already own for nearly $44 billion. WSJ's Jacob Goldstein says this is...Flash - Video

Answers for Genentech

painterjane97what does a research associate at genentech make per year?painterjane97Salaries.comACHow do you pronounce Genentech's "bevacizumab" (aka Avastin)?ACYes, pronouced like "SCI" in scissors.phildarthebuildarWhat is the stock the Motley Fool is touting as "the next Genentech?"?phildarthebuildar"Exelixis (Nasdaq: EXEL), a biotech with some promising cancer drugs in its pipeline, has returned 25% since it was recommended a year ago. Exelixis has drug partnerships with powerhouses like GlaxoSm...FrogI have a friend at Genentech but lost his e-mail address. How can I send an e-mail to him?Frog=you can't obviously e mail him but you can write him a letter or pick up the phone and call and ask for the e mail address.NJ GoldWill the FDA approval of Genentech Inc.'s (DNA) Avastin spark a near term rally in biotech?NJ GoldI've been mulling this question over ... If Obama wins big drug stocks will tank, but small bios might do very well especially if the stem cell issue gets "approved". After huffing and puffing...
Contact Us[X]
Your name
Email
Subject
Your comment
[X]